Alergologia Polska - Polish Journal of Allergology

Full text

3/2026 vol. 13
Review paper

Harmfulness of traditional and alternative tobacco and nicotine products: focusing on cardiovascular, metabolic, respiratory and cancer risk

Paulina N. Kopa-Stojak 1
,
Rafał Pawliczak 1

  1. Department of Immunopathology, Faculty of Medicine, Medical University of Lodz, Poland

Alergologia Polska – Polish Journal of Allergology 2026; 13, 3: 243-252

DOI: https://doi.org/10.5114/pja.2026.164684
Data publikacji online: 2026/10/06
Article file
PJA-Harmfullness.pdf
  1. WHO. Tobacco. Key Facts. 2022. https://www.who.int/news-room/fact-sheets/detail/tobacco. Accessed 25 Oct 2022.
  2. World Health Organization. WHO Global Report on Trends in Prevalence of Tobacco Use 2000-2025. 4th ed. Geneva: World Health Organization; 2021.
  3. Tobacco. World Health Organisation (WHO). 2025. https://www.who.int/health-topics/tobacco. Accessed 24 July 2026.
  4. World Health Organisation. Effects of tobacco on health. 2025. https://www.who.int/europe/news-room/fact-sheets/item/effects-of-tobacco-on-health. Accessed 24 July 2026.
  5. Münzel T, Hahad O, Kuntic M, et al. Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes. Eur Heart J 2020; 41: 4057-70.
  6. Chen Z, Liu X, Kenny PJ. Central and peripheral actions of nicotine that influence blood glucose homeostasis and the development of diabetes. Pharmacol Res 2023; 194: 106860.
  7. Tang M, Lee HW, Weng M, et al. DNA damage, DNA repair and carcinogenicity: tobacco smoke versus electronic cigarette aerosol. Mutat Res Rev Mutat Res 2022; 789: 108409.
  8. Laniado-Laborín R. Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21st century. Int J Environ Res Public Health 2009; 6: 209-24.
  9. Tasdighi E, Yao Z, Dardari ZA, et al. Association between cigarette smoking status, intensity, and cessation duration with long-term incidence of nine cardiovascular and mortality outcomes: the Cross-Cohort Collaboration (CCC). PLoS Med 2025; 22: e1004561.
  10. Iribarren C, Tekawa IS, Sidney S, Friedman GD. Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease, and cancer in men. N Engl J Med 1999; 340: 1773-80.
  11. Islami F, Pourshams A, Vedanthan R, et al. Smoking water-pipe, chewing nass and prevalence of heart disease: a cross-sectional analysis of baseline data from the Golestan Cohort Study, Iran. Heart 2013; 99: 272-8.
  12. Sibai AM, Tohme RA, Almedawar MM, et al. Lifetime cumulative exposure to waterpipe smoking is associated with coronary artery disease. Atherosclerosis 2014; 234: 454-60.
  13. Akter S, Okazaki H, Kuwahara K, et al. Smoking, smoking cessation, and the risk of type 2 diabetes among Japanese adults: Japan Epidemiology Collaboration on Occupational Health Study. PLoS One 2015; 10: e0132166.
  14. Yekta EM, Khodamoradi F, Beygi Z, et al. The association between smoking and metabolic syndrome: a systematic review and meta-analysis. J Public Health 2025. https://doi.org/10.1007/s10389-025-02461-w.
  15. Nath MC, Shahidur Rahman AKM, Dutta A, et al. The effect of cigarette smoking on fasting lipid profile: a single center study. Fortune J Health Sci 2022; 05: 363-73.
  16. Keith RJ, Rifai MA, Carruba C, et al. Tobacco use, insulin resistance, and risk of type 2 diabetes: results from the multi-ethnic study of atherosclerosis. PLoS One 2016; 11: e0157592.
  17. Wannamethee SG, Shaper AG, Perry IJ. Smoking as a modifiable risk factor for type 2 diabetes in middle-aged men. Diabetes Care 2001; 24: 1590-5.
  18. Sharma E, Tang Z, Lauten K, et al. Cardiovascular disease outcomes among established cigar users 40 years and older: Findings from the population assessment of tobacco and health (PATH) study, waves 1–5 (2013–2019). Prev Med Rep 2024; 37: 102569.
  19. Sepidarkish M, Rezazadeh S, Ghaffari Hamedani H, et al. The waterpipe smoking and human health: a systematic review and meta-analysis of 191 observational studies. Syst Rev 2025; 14: 74.
  20. Shafique K, Mirza SS, Mughal MK, et al. Water-pipe smoking and metabolic syndrome: a population-based study. PLoS One 2012; 7: e39734.
  21. Latif S, Saeed M. Effect of waterpipe (hookah) smoking on lipid profile, lipid peroxidation, and homocysteine levels. J Univ Med Dental Coll 2023; 14.
  22. Chung C, Lee KN, Han K, et al. Effect of smoking on the development of chronic obstructive pulmonary disease in young individuals: a nationwide cohort study. Front Med 2023; 10: 1190885.
  23. Rey-Brandariz J, Pérez-Ríos M, Ahluwalia JS, et al. Tobacco patterns and risk of chronic obstructive pulmonary disease: results from a cross-sectional study. Arch Bronconeumol 2023; 59: 717-24.
  24. Cook S, Buszkiewicz JH, Levy DT, et al. Association between cigar use, with and without cigarettes, and incident diagnosed COPD: a longitudinal cohort study. Respir Res 2024; 25: 13.
  25. Sharma E, Lauten K, Zebrak KA, et al. Respiratory symptoms and outcomes among cigar smokers: findings from the Population Assessment of Tobacco and Health (PATH) study waves 2–5 (2014–2019). Respir Res 2024; 25: 185.
  26. She J, Yang P, Wang Y, et al. Chinese water-pipe smoking and the risk of COPD. Chest 2014; 146: 924-31.
  27. Waked M, Khayat G, Salameh P. Chronic obstructive pulmonary disease prevalence in Lebanon: a cross-sectional descriptive study. Clin Epidemiol 2011; 3: 315-23.
  28. Tageldin MA, Nafti S, Khan JA, et al. Distribution of COPD-related symptoms in the Middle East and North Africa: results of the BREATHE study. Respir Med 2012; 106 Suppl 2: S25-32.
  29. Raad D, Gaddam S, Schunemann HJ, et al. Effects of water-pipe smoking on lung function: a systematic review and meta-analysis. Chest 2011; 139: 764-74.
  30. Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer – relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer 2012; 131: 1210-9.
  31. Possenti I, Miotti S, Gallus S, et al. Smoking and oral and pharyngeal cancer: a meta-analysis. Oncol Rev 2026; 19: 1672607.
  32. Long M, Fu Z, Li P, Nie Z. Cigarette smoking and the risk of nasopharyngeal carcinoma: a meta-analysis of epidemiological studies. BMJ Open 2017; 7: e016582.
  33. Rota M, Possenti I, Valsassina V, et al. Dose–response association between cigarette smoking and gastric cancer risk: a systematic review and meta-analysis. Gastric Cancer 2024; 27: 197-209.
  34. Lee YC, Cohet C, Yang YC, et al. Meta-analysis of 94 epidemiologic studies on cigarette smoking and liver cancer. Cancer Res 2007; 67 (9 Suppl): 87.
  35. Bosetti C, Lucenteforte E, Silverman DT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol 2012; 23: 1880-8.
  36. Liu X, Peveri G, Bosetti C, et al. Dose-response relationships between cigarette smoking and kidney cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2019; 142: 86-93.
  37. Zhao X, Wang yuanli, Liang C. Cigarette smoking and risk of bladder cancer: a dose–response meta-analysis. Int Urol Nephrol 2022; 54: 1169-85.
  38. Su L, Xu R, Ren Y, et al. Smoking exposure and cervical cancer risk: Integrating observational and genetic evidence. J Int Med Res 2025; 53: 03000605251383687.
  39. Sandler DP, Shore DL, Anderson JR, et al. Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. J Natl Cancer Inst 1993; 85: 1994-2003.
  40. Lee PN, Forey BA, Coombs KJ. Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer. BMC Cancer 2012; 12: 385.
  41. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg 2008; 393: 535-45.
  42. Wyss A, Hashibe M, Chuang SC, et al. Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Am J Epidemiol 2013; 178: 679-90.
  43. McCormack VA, Agudo A, Dahm CC, et al. Cigar and pipe smoking and cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2010; 127: 2402-11.
  44. Mamtani R, Cheema S, Sheikh J, et al. Cancer risk in waterpipe smokers: a meta-analysis. Int J Public Health 2017; 62: 73-83.
  45. Sadjadi A, Derakhshan MH, Yazdanbod A, et al. Neglected role of hookah and opium in gastric carcinogenesis: a cohort study on risk factors and attributable fractions. Int J Cancer 2014; 134: 181-8.
  46. Huhtasaari F, Lundberg V, Eliasson M, et al. Smokeless tobacco as a possible risk factor for myocardial infarction: a population-based study in middle-aged men. J Am Coll Cardiol 1999; 34: 1784-90..
  47. Sapundzhiev N, Werner JA. Nasal snuff: historical review and health related aspects. J Laryngol Otol 2003; 117: 686-91.
  48. Titova OE, Baron JA, Michaëlsson K, Larsson SC. Swedish snuff (snus) and risk of cardiovascular disease and mortality: prospective cohort study of middle-aged and older individuals. BMC Med 2021; 19: 111.
  49. Hergens MP, Lambe M, Pershagen G, Ye W. Risk of hypertension amongst Swedish male snuff users: a prospective study. J Intern Med 2008; 264: 187-94.
  50. Hergens MP, Galanti R, Hansson J, et al. Use of Scandinavian moist smokeless tobacco (snus) and the risk of atrial fibrillation. Epidemiology 2014; 25: 872-6.
  51. Hergens MP, Alfredsson L, Bolinder G, et al. Long-term use of Swedish moist snuff and the risk of myocardial infarction amongst men. J Intern Med 2007; 262: 351-9.
  52. Arefalk G, Hergens MP, Ingelsson E, et al. Smokeless tobacco (snus) and risk of heart failure: results from two Swedish cohorts. Eur J Prev Cardiol 2012; 19: 1120-7.
  53. Hansson J, Pedersen NL, Galanti MR, et al. Use of snus and risk for cardiovascular disease: results from the Swedish Twin Registry. J Intern Med 2009; 265: 717-24.
  54. Hu H, Nakagawa T, Honda T, et al. Association of conventional cigarette smoking, heated tobacco product use and dual use with hypertension. Int J Epidemiol 2024; 53: dyae114.
  55. Sharman A, Yermakova I, Erenchina E, et al. Respiratory function and physical capacity in combustible cigarettes and heated tobacco products users: a two-year follow-up cohort study. Global J Respir Care 2021; 7: 27-34.
  56. Lyytinen G, Melnikov G, Brynedal A, et al. Use of heated tobacco products (IQOS) causes an acute increase in arterial stiffness and platelet thrombus formation. Atherosclerosis 2024; 390: 117335.
  57. Belkin S, Benthien J, Axt PN, et al. Impact of heated tobacco products, e-cigarettes, and cigarettes on inflammation and endothelial dysfunction. Int J Mol Sci 2023; 24: 9432.
  58. Ally RM, van ZD. Tobacco use in diabetes mellitus: a retrospective cohort study to determine the effect of snuff tobacco use on diabetes mellitus complications over a period of nine years. J Endocrinol Metabol Diabetes S Afr 2024; 29: 18-23.
  59. Titova OE, Baron JA, Fall T, et al. Swedish snuff (snus), cigarette smoking, and risk of type 2 diabetes. Am J Prev Med 2023; 65: 60-6.
  60. Carlsson S, Andersson T, Araghi M, et al. Smokeless tobacco (snus) is associated with an increased risk of type 2 diabetes: results from five pooled cohorts. J Intern Med 2017; 281: 398-406.
  61. Eliasson M, Asplund K, Nasic S, Rodu B. Influence of smoking and snus on the prevalence and incidence of type 2 diabetes amongst men: the northern Sweden MONICA study. J Intern Med 2004; 256: 101-10.
  62. Östenson CG, Hilding A, Grill V, Efendic S. High consumption of smokeless tobacco (“snus”) predicts increased risk of type 2 diabetes in a 10-year prospective study of middle-aged Swedish men. Scand J Public Health 2012; 40: 730-7.
  63. Byhamre ML, Gustafsson PE, Jansson JH, et al. Snus use during the life-course and risk of the metabolic syndrome and its components. Scand J Public Health 2017; 45: 733-40.
  64. Norberg M, Stenlund H, Lindahl B, et al. Contribution of Swedish moist snuff to the metabolic syndrome: a wolf in sheep’s clothing? Scand J Public Health 2006; 34: 576-83.
  65. Øverland S, Skogen JC, Lissner L, et al. Snus use and cardiovascular risk factors in the general population: the HUNT3 study. Addiction 2013; 108: 2019-28.
  66. Hu H, Miyamoto T, Okazaki H, et al. Heated tobacco product use and abnormal glucose metabolism: a working population-based study. Acta Diabetol 2023; 60: 371-8.
  67. Jee Y, Shin SY, Ryu M, Samet JM. The effect of heated tobacco products on metabolic syndrome: a cohort study. Tob Induc Dis 2024; 22: 10.18332/tid/194490.
  68. Kim M, Lee KJ, Choi I, et al. Relationship between heated tobacco product use and low-density lipoprotein cholesterol in Korean adults: a cross-sectional study using Korea National Health and Nutrition Examination Survey 2018-2021 (VII-1 and VIII). Korean J Fam Med 2025; 46: 443-51.
  69. Hu H, Nakagawa T, Honda T, et al. Heated tobacco products and circulating high-density lipoprotein cholesterol concentrations. Sci Rep 2022; 12: 17385.
  70. Hounkpatin SHR, Flatin MC, Bouraima AF, et al. Rhinologic signs associated with snuff taking. Eur Ann Otorhinolaryngol Head Neck Dis 2020; 137: 43-5.
  71. Chetan S. Nasal muco-ciliary clearance in snuff users. J Laryngol Otol 1993; 107: 24-6.
  72. Gudnadóttir AÝ, Ólafsdóttir IS, Middelveld R, et al. An investigation on the use of snus and its association with respiratory and sleep-related symptoms: a cross-sectional population study. BMJ Open 2017; 7: e015486.
  73. Polosa R, Morjaria JB, Prosperini U, et al. Health outcomes in COPD smokers using heated tobacco products: a 3-year follow-up. Intern Emerg Med 2021; 16: 687-96.
  74. Sakaguchi C, Nagata Y, Kikuchi A, et al. Differences in levels of biomarkers of potential harm among users of a heat-not-burn tobacco product, cigarette smokers, and never-smokers in Japan: a post-marketing observational study. Nicotine Tob Res 2021; 23: 1143-52.
  75. Moazed F, Chun L, Matthay MA, et al. Assessment of industry data on pulmonary and immunosuppressive effects of IQOS. Tobacco Control 2018; 27 Suppl 1: s20-5.
  76. Harada S, Sata M, Matsumoto M, et al. Changes in smoking habits and behaviors following the introduction and spread of heated tobacco products in Japan and its effect on FEV1 decline: a longitudinal cohort study. J Epidemiol 2021; 32: 180-7.
  77. Hujoel P, Tomar S. Dry snuff is associated with a high oro-pharyngeal cancer risk in Western countries. J Evid Based Dental Pract 2003; 3: 225-6.
  78. Motlhale M, Sitas F, de Villiers CB, et al. Smokeless tobacco (snuff) and site-specific cancer risks in adult Black South African women: findings from the Johannesburg Cancer Study. Int J Cancer 2025; 156: 1916-25.
  79. Roosaar A, Johansson ALV, Sandborgh-Englund G, et al. Cancer and mortality among users and nonusers of snus. Int J Cancer 2008; 123: 168-73.
  80. Zendehdel K, Nyrén O, Luo J, et al. Risk of gastroesophageal cancer among smokers and users of Scandinavian moist snuff. Int J Cancer 2008; 122: 1095-9.
  81. Araghi M, Galanti MR, Lundberg M, et al. Smokeless tobacco (snus) use and colorectal cancer incidence and survival: results from nine pooled cohorts. Scand J Public Health 2017; 45: 741-8.
  82. Luo J, Ye W, Zendehdel K, et al. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet 2007; 369: 2015-20.
  83. Araghi M, Galanti MR, Lundberg M, et al. No association between moist oral snuff (snus) use and oral cancer: pooled analysis of nine prospective observational studies. Scand J Public Health 2021; 49: 833-40.
  84. Araghi M, Rosaria Galanti M, Lundberg M, et al. Use of moist oral snuff (snus) and pancreatic cancer: pooled analysis of nine prospective observational studies. Int J Cancer 2017; 141: 687-93.
  85. Kawasaki Y, Li YS, Watanabe S, et al. Urinary biomarkers for secondhand smoke and heated tobacco products exposure. J Clin Biochem Nutr 2021; 69: 37-43.
  86. Ohmomo H, Harada S, Komaki S, et al. DNA methylation abnormalities and altered whole transcriptome profiles after switching from combustible tobacco smoking to heated tobacco products. Cancer Epidemiol Biomarkers Prev 2022; 31: 269-79.
  87. Glantz SA, Nguyen N, Oliveira da Silva AL. Population-based disease odds for e-cigarettes and dual use versus cigarettes. NEJM Evid 2024; 3: EVIDoa2300229.
  88. Alzahrani T, Pena I, Temesgen N, Glantz SA. Association between electronic cigarette use and myocardial infarction. Am J Prev Med 2018; 55: 455-61.
  89. Vindhyal MR, Ndunda P, Munguti C, et al. Impact on cardiovascular outcomes among e-cigarette users: a review from National Health Interview Surveys. J Am Coll Cardiol 2019; 73: 11.
  90. Renard K, Nishihara D, Nilsson J, et al. Characterization of the nicotine uptake and safety of Nordic spirit tobacco-free oral nicotine pouches: a randomized cross-over study. Psychopharmacology 2025; 242: 855-65.
  91. Zhang Z, Jiao Z, Blaha MJ, et al. The association between e-cigarette use and prediabetes: results from the Behavioral Risk Factor Surveillance System, 2016–2018. Am J Prev Med 2022; 62: 872-7.
  92. Jeong W, Kim S. Impact of electronic cigarette use on the increased risk of diabetes: the Korean Community Health Survey. Epidemiol Health 2024; 46: e2024029.
  93. Cai J, Bidulescu A. The association between e-cigarette use or dual use of e-cigarette and combustible cigarette and prediabetes, diabetes, or insulin resistance: findings from the National Health and Nutrition Examination Survey (NHANES). Drug Alcohol Depend 2023; 251: 110948.
  94. Kim T, Choi H, Kang J, Kim J. Association between electronic cigarette use and metabolic syndrome in the Korean general population: a nationwide population-based study. PLoS One 2020; 15: e0237983.
  95. Cai J, Bidulescu A. Associations between e-cigarette use or dual use of e-cigarette and combustible cigarette and metabolic syndrome: results from the National Health and Nutrition Examination Survey (NHANES). Ann Epidemiol 2023; 85: 93-9.e2.
  96. Liu RH, Mizuta M, Matsukura S. Long-term oral nicotine administration reduces insulin resistance in obese rats. Eur J Pharmacol 2003; 458: 227-34.
  97. Polosa R, Morjaria JB, Caponnetto P, et al. Evidence for harm reduction in COPD smokers who switch to electronic cigarettes. Respir Res 2016; 17: 166.
  98. Campagna D, Cibella F, Caponnetto P, et al. Changes in breathomics from a 1-year randomized smoking cessation trial of electronic cigarettes. Eur J Clin Investig 2016; 46: 698-706.
  99. Cibella F, Campagna D, Caponnetto P, et al. Lung function and respiratory symptoms in a randomized smoking cessation trial of electronic cigarettes. Clin Sci 2016; 130: 1929-37.
  100. Alizadehgharib S, Lehrkinder A, Alshabeeb A, et al. The effect of a non-tobacco-based nicotine pouch on mucosal lesions caused by Swedish smokeless tobacco (snus). Eur J Oral Sci 2022; 130: e12885.
  101. Gambaryan M, Kalinina A, Popovich M, et al. Electronic cigarette use strongly associated with respiratory diseases: results from Russian Tobacco Control Policy evaluation survey. Eur Respir J 2020; 56 (suppl 64): 1875.
  102. Herriges MJ, Pinkhasov R, Shapiro O, et al. E-cigarette use and the risk of bladder and lung cancer. J Clin Oncol 2022; 40 (6 suppl): 443.
  103. Bittoni MA, Carbone DP, Harris RE. Vaping, smoking and lung cancer risk. J Oncol Res Ther 2024; 9: 10229.
  104. Kim YW, Park EJ, Kwak KI, et al. Association of electronic cigarette use after conventional smoking cessation with lung cancer risk: a nationwide cohort study. Am J Respir Crit Care Med 2024; 209 (suppl 1): A3051.
  105. Azzopardi D, Liu C, Murphy J. Chemical characterization of tobacco-free “modern” oral nicotine pouches and their position on the toxicant and risk continuums. Drug Chem Toxicol 2021; 45: 2246-54.
  106. Back S, Masser AE, Rutqvist LE, Lindholm J. Harmful and potentially harmful constituents (HPHCs) in two novel nicotine pouch products in comparison with regular smokeless tobacco products and pharmaceutical nicotine replacement therapy products (NRTs). BMC Chem 2023; 17: 9.
  107. Mallock N, Schulz T, Malke S, et al. Levels of nicotine and tobacco-specific nitrosamines in oral nicotine pouches. Tobacco Control 2024; 33: 193-9.
Copyright: © Polish Society of Allergology This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivatives 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Coverage in
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications